02  ·  Monthly Pulse

OTC & Consumer Health Pulse

Top signals across four OTC therapeutic segments, framed for consultant use. Monograph reform, Rx-to-OTC pipeline, and competitive brand moves — updated monthly by Brendan Walsh.

Edition 02  ·  May 2026

May 2026
US OTC market size
$52B
↑ 4.8% CAGR to 2028
Category disruption
PE Ruling
↓ Oral phenylephrine ruled ineffective
Fastest growing format
Topical NSAID
↑ Rx-to-OTC converts outpacing oral
Pipeline watch
Rx-to-OTC
Migraine Rx candidates in FDA review
Top five signals this month Ranked by consultant relevance
01
Respiratory Cross-category
FDA advisory panel ruling on phenylephrine triggers reformulation wave across cold-and-flu category

The September 2023 advisory panel unanimously ruled that oral phenylephrine is no effective decongestant at OTC doses. As the consequence fully propagates through retail, brands face the choice of reformulating with pseudoephedrine (behind-counter friction), switching to nasal routes, or exiting. An estimated $1.8B in PE-containing SKUs are affected in the US alone.

So what: Advise clients to accelerate reformulation decisions now. Nasal delivery systems (nasal spray, CFC-free inhaler) offer an evidence-defensible pivot. Pseudoephedrine behind-the-counter inconvenience is manageable for high-frequency users who understand efficacy.
Tier 1Federal Register — PE proposed order OTC000036
Tier 1FDA — Phenylephrine advisory ruling
Tier 2NutraIngredients USA — PE category impact

Consumer search and social signals also inform velocity rating.

Velocity
02
Gastrointestinal GLP-1 adjacency
GLP-1 GI side-effect cluster creates measurable OTC lift — no branded companion stack exists yet

Nausea, constipation, bloating, and GERD are the primary GI side effects reported by GLP-1 medication users. OTC simethicone, bismuth subsalicylate, psyllium, and omeprazole categories all showing incremental uplift tracking with GLP-1 prescription volume growth. The branded GLP-1 companion OTC opportunity remains unoccupied: no major manufacturer has launched a purpose-built GI support stack for GLP-1 users.

So what: A branded GLP-1 GI companion OTC product — combining targeted actives with a credentialed label story — is the most significant first-mover gap in the OTC segment right now. Move in 2026; by 2027 this will be crowded.
Tier 2Nutrition Insight — GLP-1 companion market data
Tier 2NutraIngredients USA — GLP-1 companion gap

Consumer search and social signals also inform velocity rating.

Velocity
03
Rx-to-OTC pipeline
Rx-to-OTC switch pipeline accelerating — migraine, contraception, and allergy candidates in active FDA review

Opill (norgestrel OTC contraceptive, approved 2023) established the precedent for high-complexity Rx-to-OTC switches. Multiple migraine candidates and a second contraceptive formulation are now in active FDA review. CARES Act administrative rulemaking continues to lower the structural barrier for monograph-eligible ingredients to gain OTC status without full NDA filing.

So what: Track the FDA Rx-to-OTC candidate docket actively. The brands who build consumer education infrastructure before switch approval — not after — capture disproportionate share of the newly addressable OTC market.
Tier 1FDA — Rx-to-OTC switch regulatory pathway
Tier 2NutraIngredients USA — Rx-to-OTC pipeline 2026

Consumer search and social signals also inform velocity rating.

Velocity
04
Dermatological
Bemotrizinol — first new FDA-proposed sunscreen active in decades signals OTC monograph modernisation in action

FDA proposed adding bemotrizinol (BEMT) to the OTC sunscreen monograph in December 2025 — the first new sunscreen active since 1999. Comment period closed January 26 2026. Final order expected June 2026, with products potentially reaching US shelves as early as late 2026. Bemotrizinol has been widely used in Europe, Australia and Asia for decades, providing strong broad-spectrum UVA/UVB protection with minimal skin absorption. This marks the first successful OTC Monograph Order Request (OMOR) under the CARES Act framework.

So what: Sunscreen brands with EU formulation experience have an immediate first-mover advantage. Begin BEMT formulation work now to be shelf-ready at final order. Brands without EU exposure should secure DSM-firmenich supply relationships now — BEMT supply will be constrained at launch.
Velocity
Tier 1Federal Register — Bemotrizinol proposed order OTC000039
Tier 2Holland & Knight — Bemotrizinol regulatory analysis
Tier 2Venable — Market entry timeline analysis

Consumer search and social signals also inform velocity rating.

05
Cross-category
Phenylephrine final order imminent — H2 2026 deadline making PE reformulation decisions unavoidable

FDA's proposed order to remove oral phenylephrine from the OTC monograph cleared its comment period in May 2025. A final order is expected no sooner than H2 2026. Brands still holding PE-containing SKUs are operating on borrowed time — reformulation timelines of 18–24 months mean decisions made now determine 2027–2028 shelf architecture. The category is bifurcating: nasal spray formats (oxymetazoline, xylometazoline) are gaining investment, while pseudoephedrine remains the only evidenced oral alternative but carries behind-counter friction.

So what: Any client without a confirmed PE reformulation decision is behind the curve. Nasal spray pivot is the cleanest evidence-defensible move. The longer the delay, the more constrained the reformulation timeline becomes before the final order lands.
Velocity
Tier 1Federal Register — PE proposed order OTC000036
Tier 1FDA — Phenylephrine advisory committee ruling

Consumer search and social signals also inform velocity rating.

Products to watch
GLP-1 GI companion OTC
No branded product exists. Simethicone + psyllium + ginger + B6 claim frame is defensible and addressable under existing monograph actives. First-mover window: 2026.
Topical CBD analgesic
High consumer demand. FDA regulatory posture on CBD OTC unresolved. Monitor for administrative guidance. Topical route avoids most of the systemic safety concerns that stall oral CBD.
Zinc lozenge (cold)
Cochrane-backed evidence for cold duration. Lozenge format is the only evidence-supported delivery form. Mainstream retail distribution still underpenetrated relative to evidence strength.
Niacinamide OTC crossover
Cosmeceutical to OTC transition building. Hyperpigmentation + skin barrier claims. Regulatory boundary between cosmetic and drug claim is the constraint to navigate carefully.
Regulatory watch
UrgentPhenylephrine (oral) — FDA advisory ruling (Sep 2023) now being actioned at brand/retail level. Reformulation timeline is the key client decision. Brands without a plan are at category risk.
WatchOTC monograph modernisation — CARES Act 2020 established administrative pathway. New ingredient approvals and reformulation flexibility expected in H2 2026 rulemaking cycle.
WatchTopical CBD — FDA still has not established regulatory framework for OTC topical CBD products. State-level rules vary. Claim architecture must be defensible without FDA clarity.
MonitorRx-to-OTC switch docket — check FDA OTC monograph database quarterly. Migraine and contraception candidates are the nearest-term approvals to watch.